Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Early Bottlenecks in Developing Biopharmaceutical Products Delay Commercialization

22.08.2014

An analysis of patented university inventions licensed to biotechnology firms has revealed early bottlenecks on the path to commercialization. To open these roadblocks, the researchers suggest that better communication of basic research results during the discovery stage could lead to faster commercialization down the road.

Biopharmaceutical drugs are frequently derived from discoveries made in university laboratories and licensed to biotechnology firms. Bottlenecks are well known during clinical trials, which have a high failure rate.


Georgia Institute of Technology

From left to right, Jerry Thursby, Matthew Higgins and Marie Thursby. The research team identified bottlenecks in the development of biopharmaceutical products and proposes a way to avoid the setbacks.

But a new study pinpoints how much time is lost earlier in the pathway, when biotech companies give up on an invention and transfer the technology to other biotech firms for repurposing in a new disease category.

Companies rarely share their basic research on an invention, which highlights what the researchers consider to be an underappreciated cost of commercialization as basic science research is then repeated, postponed, or never performed.

“The timeline for commercialization is much longer than most people think. There is so much turmoil and churn within the process,” said co-author Jerry Thursby, a professor and the Ernest Scheller, Jr. Chair in Innovation, Entrepreneurship, and Commercialization at the Scheller College of Business at the Georgia Institute of Technology.

The study was sponsored by the National Institutes of Health (NIH) and was published August 20 in the journal Science Translational Medicine.

The standard path to the marketplace for biotechnology is for universities to do most of the basic research and then license a discovery to a small biotechnology firm that advances the research. The small biotech firm will then sublicense the discovery to a large biotechnology firm that can afford to run clinical trials.

The study found that basic research rarely proceeds in this straightforward path to commercialization, often zigzagging across biotech firms and research areas before a drug is finally developed.

“What these data reveal is that there’s a lot of bench to bench translational research. It’s not linear,” said Marie Thursby, a study co-author and the Hal and John Smith Chair in Entrepreneurship at the Scheller College of Business. Matthew Higgins, an associate professor of strategic management, was also a co-author of the study.

For the study, the researchers built a database of 835 patents in 342 university licenses with biotech firms. The researchers then traced the path of patents to document whether they were subsequently sublicensed to another firm for testing in a new disease category or whether the sublicense was to a large firm for clinical trials or marketing. Sublicensing often resets the development timeline in what the authors refer to as bench-to-bench translational research.

“A very large fraction of the time, an invention pops out as something else and the timeline for the discovery stage starts all over again,” said Jerry Thursby.
Of the 835 inventions studied, 27 percent appeared in a second license. The average time between invention and first license was five and a half years, and the average time between first- and second-license was three and a half years.

This time span for the upstream phase of the translation process is substantial, the study says, given that the average time from discovery to approval of new drugs (including biologics) by the U.S. Food and Drug Administration (FDA) is 13 years.

Of the first-licenses that list a stage of development, 92 percent were either at the discovery or lead molecule stages (the earliest two stages, respectively), with only 6 percent listed in clinical trials. Among the second-licenses, only 22 percent were in clinical trials or beyond.

“Nobody knew the magnitude of how much licensing changes and the stages at which they change,” said Marie Thursby. “The biotechnology industry is quite fragmented, and there are all sorts of informational problems.”

This analysis of early-stage biomedical translation suggests that stakeholders need to design policies and initiatives that enhance early translation by more efficiently driving more inventions into multiple disease pipelines.

One option might be the formation of an open-source translational research database that complements clinicaltrials.gov, where patents and licenses for fundamental biomedical research believed to be destined for eventual therapeutic use initially would be logged and shared.

“What might be a failure to a biotech firm could be a success to society as a whole,” Jerry Thursby said.

This research is supported and based on three separate subcontracts with the Office of Science Policy Analysis, Office of the Director, National Institutes of Health, under award number HHSN26320100002IC. Any conclusions or opinions are those of the authors and do not necessarily represent the official views of the sponsoring agency.

CITATION: Marie Thursby, et al., “Bench-to-Bench Bottlenecks in Translation.” (Science Translational Medicine, August 2014).

Research News
Georgia Institute of Technology
177 North Avenue
Atlanta, Georgia 30332-0181 USA
@GTResearchNews

Contact Information

Brett Israel
Communications Officer II
brett.israel@comm.gatech.edu
Phone: 404-385-1933

Brett Israel | newswise

More articles from Studies and Analyses:

nachricht High in calories and low in nutrients when adolescents share pictures of food online
07.04.2016 | University of Gothenburg

nachricht Brain connectivity reveals hidden motives
04.03.2016 | Universität Zürich

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Nuclear Pores Captured on Film

Using an ultra fast-scanning atomic force microscope, a team of researchers from the University of Basel has filmed “living” nuclear pore complexes at work for the first time. Nuclear pores are molecular machines that control the traffic entering or exiting the cell nucleus. In their article published in Nature Nanotechnology, the researchers explain how the passage of unwanted molecules is prevented by rapidly moving molecular “tentacles” inside the pore.

Using high-speed AFM, Roderick Lim, Argovia Professor at the Biozentrum and the Swiss Nanoscience Institute of the University of Basel, has not only directly...

Im Focus: 2+1 is Not Always 3 - In the microworld unity is not always strength

If a person pushes a broken-down car alone, there is a certain effect. If another person helps, the result is the sum of their efforts. If two micro-particles are pushing another microparticle, however, the resulting effect may not necessarily be the sum their efforts. A recent study published in Nature Communications, measured this odd effect that scientists call “many body.”

In the microscopic world, where the modern miniaturized machines at the new frontiers of technology operate, as long as we are in the presence of two...

Im Focus: Tiny microbots that can clean up water

Researchers from the Max Planck Institute Stuttgart have developed self-propelled tiny ‘microbots’ that can remove lead or organic pollution from contaminated water.

Working with colleagues in Barcelona and Singapore, Samuel Sánchez’s group used graphene oxide to make their microscale motors, which are able to adsorb lead...

Im Focus: ORNL researchers discover new state of water molecule

Neutron scattering and computational modeling have revealed unique and unexpected behavior of water molecules under extreme confinement that is unmatched by any known gas, liquid or solid states.

In a paper published in Physical Review Letters, researchers at the Department of Energy's Oak Ridge National Laboratory describe a new tunneling state of...

Im Focus: Bionic Lightweight Design researchers of the Alfred Wegener Institute at Hannover Messe 2016

Honeycomb structures as the basic building block for industrial applications presented using holo pyramid

Researchers of the Alfred Wegener Institute (AWI) will introduce their latest developments in the field of bionic lightweight design at Hannover Messe from 25...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

The “AC21 International Forum 2016” is About to Begin

27.04.2016 | Event News

Soft switching combines efficiency and improved electro-magnetic compatibility

15.04.2016 | Event News

Grid-Supportive Buildings Give Boost to Renewable Energy Integration

12.04.2016 | Event News

 
Latest News

New fabrication and thermo-optical tuning of whispering gallery microlasers

04.05.2016 | Physics and Astronomy

Introducing the disposable laser

04.05.2016 | Physics and Astronomy

A new vortex identification method for 3-D complex flow

04.05.2016 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>